| DB ID | MyCo_7086 |
| Title | Using (1,3)-β-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis |
| Year | 2023 |
| PMID | 37872649 |
| Fungal Diseases involved | Eumycetoma |
| Associated Medical Condition | None |
| Genus | Madurella |
| Species | mycetomatis |
| Organism | Madurella mycetomatis |
| Ethical Statement | Informed consent was obtained from participants prior to enrol-ment, according to guidelines from the ethical committee at the Soba University Hospital, Khartoum, Sudan. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | Netherlands |
| Cohort | Patients with PCR-confirmed eumycetoma caused by M. myce- tomatis were enrolled in a DNDi-sponsored, randomized, double- blinded, phase II proof-of-concept trial comparing fosravuconazole therapy with itraconazole for the treatment of eumycetoma. In this study, here measured (1,3)-β-D-glucan concentrations in serum with the WAKO (1,3)-β-D-glucan assay in 104 patients with eumycetoma treated with either 400 mg itraconazole daily, or 200 mg or 300 mg fosravuconazole weekly. |
| Cohort No. | 104 |
| Age Group | 15–77 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Eumycetoma is a neglected tropical disease of the subcutaneous tissue that is endemic in tropical and subtropical regions. It is most commonly caused by the fungus Madurella mycetomatis. The dis-ease is characterized by the presence of painless tumorous lesions which can discharge grains. Eumycetoma is treated by a combination of antifungal therapy and surgery. Typically, once a diagnosis has been made, treatment is initiated with an azole for a period of 6 months. After this, the lesion is surgically removed and then an- other 6 months of azole treatment is given to prevent recurrent in- fection. The recommended azole is itraconazole, which is given in a daily dose of 400 mg. Fosravuconazole was under clinical investigation in a DNDi-sponsored phase II clinical trial (NCT03086226) where it was being given in weekly doses of 200 mg or 300 mg for a duration of 12 months. |
| Technique | Assay |
| Analysis Method | WAKO (1,3)-β-D-glucan assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | WAKO (1,3)-β-D-glucan assay |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
